NASDAQ$WGS
GeneDx Holdings Corp · Q2 2025 earnings
Q2 2025 earnings · · After market close
Briefing
GeneDx Holdings Corp reported strong sequential and year-over-year revenue growth in Q2 2025, driven by increased whole exome and genome sequencing volumes and improved reimbursement rates.
For the three months ended June 30, 2025, the company achieved total revenue of $102.7 million, representing a 46% increase from the prior year, with diagnostic test revenue reaching $99.8 million. Net income was $10.8 million, or $0.38 per basic share, compared to a net loss in the prior year period. Gross margin improved to 69.0% due to favorable test mix shift toward higher-margin exome and genome tests.
- Total revenue grew 46% year-over-year to $102.7 million, led by 69% growth in whole exome and genome sequencing revenue.
- Exome and genome test volumes increased 28% to 23,102 tests, representing 41% of total test results.
- Gross profit rose 65% to $70.9 million, with gross margin expanding to 69.0% from 60.9% in Q2 2024.
- Net income of $10.8 million reflected improved operating leverage and a favorable change in fair value of warrants.
Headline financials
Revenue & EPS history
GeneDx Holdings Corp · Revenue · Quarterly
$103M
Revenue by segment
GeneDx Holdings Corp · $103M total across 2 segments · Q2 2025
- Diagnostic test revenue$99.8M—97.2%
- Other revenue$2.87M—2.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports
-0.2%
Avg return
Earnings day
-7.5%
Avg return
5 days after
-10.6%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+49.9%
Q3 2024
Best reaction
-42.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +3.8% | -37.6% | -18.8% | |
| Q4 2025 | +6.1% | -2.9% | -18.4% | |
| Q3 2025 | +5.2% | +4.8% | +26.7% | |
| Q1 2025 | -42.8% | -43.4% | -39.1% | |
| Q3 2024 | +49.9% | +38.7% | +41.7% | |
| Q2 2024 | -10.6% | -10.7% | -3.6% | |
| Q1 2024 | -0.7% | +77.4% | +90.9% | |
| Q3 2023 | -1.1% | -20.7% | -2.2% | |
| Q2 2023 | -0.6% | -21.2% | -34.1% | |
| Q1 2023 | -5.6% | -22.2% | -24.3% | |
| Q3 2022 | -12.2% | -39.0% | -70.8% | |
| Q2 2022 | -1.2% | -51.0% | -58.8% | |
| Q1 2022 | +10.3% | +32.1% | +1.9% | |
| Q3 2021 | -2.5% | -9.2% | -39.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro